NeuroPace Industry Supported Non-CME Satellite Symposium

IGE Management in the Era of Neuromodulation

Saturday, December 5th, 2026 | 6:00 - 9:00pm MT

Bluebird 3D-H, Colorado Convention Center

Join us for an evening exploring the evolving evidence for neuromodulation in drug-resistant IGE. We'll discuss the burden of uncontrolled IGE, the latest 24-month evidence from the NAUTILUS clinical trial, and a neurosurgeon's perspective on expediting access to care for patients who continue to have seizures despite adequate medication trials.

Faculty

Samden Lhatoo, Chair, Neurology, UT Health Houston

Martha Morrell, Chief Medical Officer, NeuroPace

Mark Richardson, Director, Functional Neurosurgery, Massachusetts General Hospital

U.S. HCPs only. Group meals will be covered by NeuroPace, Inc. and reported in accordance with Open Payments (Sunshine Act). Space is limited, please register early. CAUTION – Investigational device. Limited by US law to investigational use for Idiopathic Generalized Epilepsy (IGE). © 2026 NeuroPace, Inc. All rights reserved. NeuroPace and RNS are registered trademarks of NeuroPace, Inc., Mountain View, CA. NP 260174 Rev1 / Rev Date 2026-09